Duration of Influenza Virus Shedding among HIV-Infected Adults in the cART Era, 2010-2011

AIDS Research and Human Retroviruses

Volumn 32, Issue 12, 2016, Pages 1180-1186

  Patel, Pragna ^a   Bush, Timothy ^a   Kojic, E Milu ^b   Overton, Edgar T ^c   Henry, Keith ^d   Önen, Nur ^e   Rhame, Frank ^f   Conley, Lois ^a   Brooks, John T ^a   Fry, Alicia ^g  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ABBOTT NORTHWESTERN HOSPITAL   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

HIV; influenza; shedding

Indexed keywords

OSELTAMIVIR; ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL COUNT; COHORT ANALYSIS; COMPARATIVE STUDY; COUGHING; DISEASE DURATION; DISEASE SURVEILLANCE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEN WHO HAVE SEX WITH MEN; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUARANTINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SORE THROAT; TREATMENT DURATION; VIRUS ISOLATION; VIRUS LOAD; VIRUS SHEDDING; COMPLICATION; ISOLATION AND PURIFICATION; NASOPHARYNX; ORTHOMYXOVIRIDAE; TIME FACTOR; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NASOPHARYNX; ORTHOMYXOVIRIDAE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; TIME FACTORS; VIRUS SHEDDING;

EID: 85006056937     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2015.0349     Document Type: Article

References (31)

1. Lee N, Chan PKS, Hui DSC, Rainer TH, Wong E, Choi KW, et al.: Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009;200:492-500.
2. Ryoo SM, Kim WY, Sohn CH, Seo DW, Oh BJ, Lee JH, et al.: Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days. Influenza Other Respir Viruses 7:833-837.
3. Meschi S, Selleri M, Lalle E, Bordi L, Valli MB, Ferraro F, et al.: Duration of viral shedding in hospitalized patients infected with pandemic H1N1. BMC Infect Dis 2011;11:140.
4. Na S, Chong YP, Kim MN, Kim WY, Kim W, Hong SB, et al.: Duration of viral shedding in patients admitted to hospital with pandemic influenza A/H1N1 2009 infection. J Med Virol 2011;83:5-9.
5. Waiboci LW, Lebo E, Williamson JM, Mwiti W, Kikwai GK, Njuguna H, et al.: Viral shedding in patients infected with pandemic influenza A (H1N1) virus in Kenya, 2009. PLoS One 2011;6:e20320.
6. Klein MB, Lu Y, DelBaso L, Cote S, Boivin G: Influenza virus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 2007;45:234-240.
7. Cohen JP, Macauley C: Susceptibility to influenza A in HIV-positive patients. JAMA 1989;261:245.
8. Thurn JR, Henry K: Influenza A pneumonitis in a patient infected with human immunodeficiency virus (HIV). Chest 1989;95:807-810.
9. Safrin S, Rush JD, Mills J: Influenza in patients with human immunodeficiency virus infection. Chest 1990;98:33-37.
10. Radwan HM, Cheesman SH, Lai KK, Ellison IR: Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis 2000;31:604-606.
11. Neuzil KM, Reed GW, Mitchel EF Jr, Griffen MR: Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999;281:901-907.
12. Lin JC, Nichol KL: Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001;161:441-446.
13. Baz M, Abed Y, McDonald J, Boivin G: Characterization of multidrug-resistant influenza A/H3N2 viruses shed dur-ing 1 year by an immunocompromised child. Clin Infect Dis 2006;43:1555-1561.
14. Boivin G, Goyette N, Bernatchez H: Prolonged excretion of amantadine-resistant influenza A virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infec Dis 2002;34:e23-e25.
15. Gooskens J, Jonges M, Claas EC, Meijer A, Kroes ACM: Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 2009;199:1435-1441.
16. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ: Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: Detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995;172:1352-1355.
17. Weinstock DM, Gubareva LV, Zuccotti G: Prolonged shedding of multidrug-resistant influenza virus in an immunocompromised patient. N Engl J Med 2003;348:867-868.
18. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG: Recovery of drug-resistant influenza virus from immunocompromised patients: A case series. J Infect Dis 2006;193: 760-764.
19. van der Vries E, van den Berg B, Scutten M: Fatal Oseltamivir-resistant influenza virus infection. N Engl J Med 2008;359:1074-1076.
20. Pemberton RM, Jennings R, Potter CW, Oxford JS: Amantadine resistance in clinical influenza A (H3N2) and (H1N1) virus isolates. J Antimicrob Chemoth 1986;18: 135-140.
21. Le QM, Kiso M, Someya K, et al.: Avian flu: Isolation of drug-resistant H5N1 virus. Nature 2005;437:1108.
22. Herlocher ML, Truscon R, Elias S, et al.: Influenza viruses resistant to the antiviral drug oseltamivir: Transmission studies in ferrets. J Infect Dis 2004;190:1627-1630.
23. CDC: Monitoring selected national HIV prevention and care objectives by using HIV surveillance data - United States and 6 dependent areas - 2012. HIV Surveillance Supplemental Report 2014;19 (No. 3). Published November 2014.
24. Vellozzi C, Brooks JT, Bush T, et al.: The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN study). Am J Epidemiol 2009;169: 642-652.
25. Hilton JF: The appropriateness of the Wilcoxon test in ordinal data. Stat Med 1996;15:631-645.
26. Fiore AE, Fry A, Shay D, et al.: Antiviral agents for the treatment and chemoprophylaxis of influenza - Recommendations of theAdvisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60:1-24.
27. Ling LM, Chow AL, Lye DC, Tan AS, Krishnan P, Cui L, et al.: Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010;50:963-969.
28. Leung YH, Lim WL, Wong MH, Chuang SK: Delayed oseltamivir treatment is associated with longer viral shedding of pandemic (H1N1) 2009 virus. Epidemiol Infect 2012;140:814-817.
29. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE: Local and systemic cytokine responses during experimental human influenza A virus infection: Relation to symptom formation and host defense. J Clin Invest 1998;101:643-649.
30. Lau LL, Cowling BJ, Fang VJ, Kwok-Hung C, Lau EHY, Lipsitch M, et al.: Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis 2010;201:1509-1516.
31. Centers for Disease Control and Prevention: Update: Influenza activity - United States, 2010-2011 season, and composition of the 2011-2012 influenza vaccine. MMWR Morb Mortal Wkly Rep 2011;60:705-712.